Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy

Gerald H J Mickisch, Björn Schwander, Bernard Escudier, Joaquim Bellmunt, José P. Maroto, Camillo Porta, Stefan Walzer, Uwe Siebert

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy'. Together they form a unique fingerprint.

Medicine & Life Sciences

Business & Economics

Social Sciences